"Implementation of the Drug Policy Control Order (DPCO) 2013 by the New Pharmaceutical Pricing Authority (NPPA) with effect from May 15, 2013, which put a cap on the prices of 348 essential drugs, is likely to impact domestic revenue generation of both homegrown and multinational drug companies in 2014," Dun & Bradstreet said in its report.
The impact of the new drug pricing policy and regulatory intervention has already started influencing the growth performance of the overall pharma industry.
Compliance to this regulation may continue to create the pressure on pharma companies' profitability in 2014, it said.
The pharma industry has exhibited a stellar performance in the past and has grown unabated at an estimated CAGR of 13 per cent during FY2009-13, driven by domestic and export-led demand.
Though the pharma industry has remained shock-proof to recession in the past, currently companies in this sector are also facing the heat of slowing economic growth.
The cumulative sale for first nine months of 2013 grew by just 9 per cent against 17.4 per cent in the previous year.
Moreover, the industry is facing stringent regulatory and quality norms both at global and domestic front.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
